中國醫藥大學 |
2008-05-31 |
HBP1對口腔癌細胞上皮成長因子受器 EGFR-β-Catenin的訊息傳遞之抑制
|
黃俊瑩(Huang, Chun-Yin) |
中國醫藥大學 |
2007-08-31 |
HBP1抑制乳癌細胞上皮成長因子受體的訊息傳遞
|
黃俊瑩(Huang, Chun-Yin) |
國立臺灣大學 |
2009 |
Hbsag Clearance Continues to Increase Post-Treatment in Patients with Hcv Hbv Coinfection Treated with Peginterferon Alfa-2a Plus Ribavirin: 1.5 Year Follow-Up
|
劉俊人; 吳順生; 趙有誠; 楊賢馨; 林志陵; 高嘉宏; 劉振驊; 陳培哲; 陳定信; 莊萬龍; 李全謨; 余明隆; 盧勝男; LIU, CHUN-JEN; WU, SHUN-SHENG; CHAO, YOU- CHEN; YANG, SIEN-SING; LIN, CHIH-LIN; KAO, JIA-HORNG; LIU, CHEN-HUA; CHEN, PEI-JER; CHEN, DING-SHINN; CHUANG, WAN-LONG; LEE, CHUAN-MO; YU, MING-LUNG; LU, SHENG-NAN |
臺大學術典藏 |
2018-09-10T03:32:37Z |
HBsAg in placentas
|
Lin, H.-H.; HO-HSIUNG LIN |
國立臺灣大學 |
1989 |
HBsAg in Placentas
|
林鶴雄; Lin, Ho-Hsiung |
臺大學術典藏 |
2021-03-03T03:01:44Z |
HBsAg in placentas
|
Ho-Hsiung Lin; HO-HSIUNG LIN |
臺大學術典藏 |
2020-02-17T08:51:17Z |
HBsAg in placentas
|
HO-HSIUNG LIN |
臺大學術典藏 |
2018-09-10T08:04:10Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu, M.-L. and Lee, C.-M. and Chuang, W.-L. and Lu, S.-N. and Dai, C.-Y. and Huang, J.-F. and Lin, Z.-Y. and Hu, T.-I. and Chen, C.-H. and Hung, C.-. and Wang, J.-H. and Chen, C.-L. and Kao, J.-H. and Lai, M.-Y. and Liu, C.-H. and Su, T.-H. and Wu, S.-S. and Liao, L.-Y. and Kuo, H.-T. and Chao, Y.-C. and Tung, S.-Y. and Yang, S.-S. and Chen, P.-J. and Liu, C.-J. and Chen, D.-S.; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; TUNG-HUNG SU; DING-SHINN CHEN; JIA-HORNG KAO |
臺大學術典藏 |
2021-03-09T01:47:46Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; TUNG-HUNG SU; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
臺大學術典藏 |
2021-05-24T07:20:50Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; CHEN-HUA LIU; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
臺大學術典藏 |
2021-09-04T06:12:14Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; JIA-HORNG KAO; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
臺大學術典藏 |
2022-01-25T05:10:33Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; CHI-LING CHEN; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
臺大學術典藏 |
2022-01-24T09:31:58Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; CHUN-JEN LIU; Chen D.-S. |
臺大學術典藏 |
2021-07-03T03:34:42Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; PEI-JER CHEN; Liu C.-J.; Chen D.-S. |
高雄醫學大學 |
2010 |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
|
余明隆;李詮謀;莊萬龍;盧勝男;戴嘉言;黃志富;林子堯;胡琮輝;陳建宏;洪肇宏;王景弘;高嘉宏;賴明陽;劉振驊;蘇東弘;廖麗瑛;郭行道;趙有誠;董水義;楊賢馨;陳培哲;劉俊人;陳定信 ; Yu ML;Lee CM;Chuang WL;Lu SN;Dai CY;Huang JF;Lin ZY;Hu TH;Chen CH;Hung CH;Wang JH;Chen CL;Kao JH;Lai MY;Liu CH;Su TH;Wu SS;Liao LY;Kuo HT;Chao YC;Tung SY;Yang SS;Chen PJ;Liu CJ;Chen DS. |
國立臺灣大學 |
2009 |
Hbsag Seroclearance: The More and Earlier, the Better
|
曾岱宗; 高嘉宏; TSENG, TAI-CHUNG; KAO, JIA-HORNG |
臺大學術典藏 |
2018-09-10T07:39:49Z |
HBsAg Seroclearance: The More and Earlier, the Better
|
Tseng, Tai-Chung;Kao, Jia-Horng; JIA-HORNG KAO; TSENG, TAI-CHUNG; KAO, JIA-HORNG |
臺大學術典藏 |
2021-09-04T06:12:30Z |
HBsAg Seroclearance: The More and Earlier, the Better
|
Tseng T.; JIA-HORNG KAO |
臺大學術典藏 |
2021-06-24T06:46:54Z |
HBsAg, HBsAb, immunoglobulins and C3 in primary nephrotic syndrome
|
WAN-YU CHEN; Chuang C.Y.; Chen D.S.; Wang T.H.; Yen T.S.; Hsieh B.S.; Lin M. |
高雄醫學大學 |
2011 |
HBsAg-seropositive Advanced Hepatocellular Carcinoma Patients with Everolimus, a mTOR inhibitor, therapy: Change of Serum HBV DNA Titer and Hepatitis Flare-up
|
戴嘉言;夏和雄;張俊彥;莊萬龍;陳立宗 |
元智大學 |
2005-10 |
HBT nonlinear current characterization for Volterra analysis
|
陳冠宇; 黃建彰 |
元智大學 |
2005-10 |
HBT nonlinear current characterization for Volterra analysis
|
陳冠宇; 黃建彰 |
國立交通大學 |
2014-12-13T10:29:48Z |
HBT 電晶體小訊號Pi模型之解析式的解法
|
胡樹一; Hu Shu-I |
元智大學 |
2004 |
HBT元件非線性現象分析與HBT元件應用在Wireless LAN802.11a之設計
|
陳冠宇; Kuan-Yu Chen |
高雄醫學大學 |
2000 |
hBUB1在骨髓性急性白血病之表現
|
林勝豐;林柏每;楊名琦;劉大智;張建國;蘇裕傑;陳田柏 |